Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Ajanta Pharma is a specialty branded generics company with a leadership focus in ophthalmology, dermatology, cardiology and pain management in India, plus large branded-generic franchises in Asia and Africa. It also sells generics in the US and supplies anti-malarials institutionally in Africa. Revenue is driven by branded prescription growth in India and emerging markets, with a track record of first-to-market brand launches; manufacturing spans multiple USFDA-approved plants.
A high-margin mid-cap branded generics player with strong emerging-market franchises.
Ajanta Pharmaceuticals Ltd. is a constituent of NIFTY 500, NIFTY MIDCAP 150, NIFTY PHARMA. See where it sits on the market heatmap →
Consolidated annual figures taken from Ajanta Pharmaceuticals Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 84.53 | 73.56 | 64.82 |
| Book value / share (₹) | 361.16 | 302.38 | 282.34 |
| Return on equity | 23.3% | 24.3% | 22.9% |
| Return on capital employed | 25.8% | 27.8% | 27.7% |
| Operating margin | 22.4% | 24.0% | 24.6% |
| Net margin | 19.4% | 19.8% | 19.4% |
| EBITDA | ₹1,395 Cr | ₹1,260 Cr | ₹1,172 Cr |
| Free cash flow | ₹164 Cr | ₹839 Cr | ₹633 Cr |
| Total debt | ₹212 Cr | ₹3 Cr | ₹1 Cr |
| Debt to equity | 0.05 | 0.00 | 0.00 |
| Interest coverage | 75.8 | 53.8 | 143.8 |
| Current ratio | 2.64 | 2.84 | 3.04 |
| Shares outstanding | 12,53,50,000 | 12,53,50,000 | 12,63,50,000 |
Open the full income statement, balance sheet and cash flow for AJANTPHARM →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.